PERISINK – Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Description

This project will be carried out in collaboration with InCephalo, a preclinical-stage biotech company developing innovative therapies for CNS diseases. It focuses on further advancing the companies' proprietary C-Lock platform, mediating prolonged retention of therapeutic molecules within the CNS compartment. We will here develop glycan-optimized variants of biologics, enabling tunable systemic half-life without compromising activity.